Levels of circulating endothelial cells are low in idiopathic pulmonary fibrosis and are further reduced by anti-fibrotic treatments
Authors:
- Sara De BiasiSBSara De Biasi
- Stefania CerriSCStefania Cerri
- Elena BianchiniEBElena Bianchini
- Lara GibelliniLGLara Gibellini
- Elisa PersianiEPElisa Persiani
- Gloria MontanariGMGloria Montanari
- Fabrizio LuppiFLFabrizio Luppi
- Cristiano Matteo CarbonelliCCCristiano Matteo Carbonelli
- Luigi ZucchiLZLuigi Zucchi
- Marialuisa BocchinoMBMarialuisa Bocchino
- Alessandro Sanduzzi ZamparelliAlessandro Sanduzzi Zamparelli
- Carlo VancheriCVCarlo Vancheri
Open Access
- 9 November 2015
- journal article
- research article
- Published by Springer Nature in BMC Medicine
- Vol. 13 (1) , 1-10
Abstract
It has been suggested that circulating fibrocytes and endothelial cells actively participate in the intense remodelling of the pulmonary vasculature in patients with idiopathic pulmonary fibrosis (IPF). Indeed, fibrotic areas exist that have fewer blood vessels, whereas adjacent non-fibrotic tissue is highly vascularized. The number of circulating endothelial cells (CEC) and endothelial progenitor cells (EPC) might reflect the balance between vascular injury and repair. Thus, fibrocytes as well as endothelial cells could potentially be used as biomarkers of disease progression and treatment outcome. Peripheral blood samples were collected from 67 patients with a multidisciplinary diagnosis of IPF and from 45 age-matched and sex-matched healthy volunteers. Buffy coat was isolated according to standard procedures and at least 20 million cells were stained with different monoclonal antibodies for the detection of CEC, EPC and circulating fibrocytes. For the detection of CEC and EPC, cells were stained with anti-CD45, anti-CD34, anti-CD133, anti-CD14, anti-CD309 and with the viability probe Far-Red LIVE/DEAD. For the detection of circulating fibrocytes, cells were first stained with LIVE/DEAD and the following monoclonal antibodies: anti-CD3, anti-CD19, anti-CD45, anti-CD34 and anti-CD14, then cells were fixed, permeabilized and stained with fluorochrome-conjugated anti-collagen I monoclonal antibodies. Patients with IPF displayed almost undetectable levels of circulating fibrocytes, low levels of CEC, and normal levels of EPC. Patients treated with nintedanib displayed higher levels of CEC, but lower levels of endothelial cells expressing CD309 (the type II receptor for vascular endothelial growth factor). Treatment with both nintedanib and pirfenidone reduced the percentage of CEC and circulating fibrocytes. Levels of CEC were reduced in patients with IPF as compared to healthy individuals. The anti-fibrotic treatments nintedanib and pirfenidone further reduced CEC levels. These findings might help explain the mechanism of action of these drugs and should be explored as predictive biomarkers in IPF.Keywords
Funding Information
- AIFA (MRAR08C010)
This publication has 39 references indexed in Scilit:
- Endothelial Progenitor Cells in the Pathogenesis of Idiopathic Pulmonary Fibrosis: An Evolving ConceptPLOS ONE, 2013
- T Cell Activation but Not Polyfunctionality after Primary HIV Infection Predicts Control of Viral Load and Length of the Time without TherapyPLOS ONE, 2012
- Imbalance of circulating endothelial cells and progenitors in idiopathic pulmonary fibrosisAngiogenesis, 2012
- Peripheral blood biomarkers in idiopathic pulmonary fibrosisTranslational Research, 2012
- An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and ManagementAmerican Journal of Respiratory and Critical Care Medicine, 2011
- New Mechanisms of Pulmonary FibrosisChest, 2009
- Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosisEuropean Respiratory Journal, 2007
- Circulating peripheral blood fibrocytes in human fibrotic interstitial lung diseaseBiochemical and Biophysical Research Communications, 2007
- Angiogenic cytokines in patients with idiopathic interstitial pneumoniaThorax, 2004
- Circulating fibrocytes: collagen-secreting cells of the peripheral bloodThe International Journal of Biochemistry & Cell Biology, 2004